JP2013545459A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545459A5
JP2013545459A5 JP2013537859A JP2013537859A JP2013545459A5 JP 2013545459 A5 JP2013545459 A5 JP 2013545459A5 JP 2013537859 A JP2013537859 A JP 2013537859A JP 2013537859 A JP2013537859 A JP 2013537859A JP 2013545459 A5 JP2013545459 A5 JP 2013545459A5
Authority
JP
Japan
Prior art keywords
variant
fviii
seq
factor viii
hemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545459A (ja
JP5922141B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059297 external-priority patent/WO2012061689A2/en
Publication of JP2013545459A publication Critical patent/JP2013545459A/ja
Publication of JP2013545459A5 publication Critical patent/JP2013545459A5/ja
Application granted granted Critical
Publication of JP5922141B2 publication Critical patent/JP5922141B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537859A 2010-11-05 2011-11-04 増加した比活性を有する抗血友病第viii因子の新規変異体 Expired - Fee Related JP5922141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
US61/410,437 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (3)

Publication Number Publication Date
JP2013545459A JP2013545459A (ja) 2013-12-26
JP2013545459A5 true JP2013545459A5 (https=) 2014-12-11
JP5922141B2 JP5922141B2 (ja) 2016-05-24

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537859A Expired - Fee Related JP5922141B2 (ja) 2010-11-05 2011-11-04 増加した比活性を有する抗血友病第viii因子の新規変異体

Country Status (18)

Country Link
US (2) US9150637B2 (https=)
EP (1) EP2635297B1 (https=)
JP (1) JP5922141B2 (https=)
KR (1) KR101948337B1 (https=)
CN (1) CN103298483B (https=)
AU (1) AU2011323236B2 (https=)
BR (1) BR112013011041B1 (https=)
CA (1) CA2816575C (https=)
CO (1) CO6720990A2 (https=)
DK (1) DK2635297T3 (https=)
EA (1) EA035447B1 (https=)
ES (1) ES2721478T3 (https=)
IL (1) IL226158B (https=)
MX (2) MX347503B (https=)
MY (1) MY165089A (https=)
SG (2) SG10201509149VA (https=)
WO (1) WO2012061689A2 (https=)
ZA (1) ZA201303816B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α1プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
DK1194161T3 (da) 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AU2002364509A1 (en) 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) * 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Similar Documents

Publication Publication Date Title
DK2864360T3 (en) TARGETED THERAPY
CN110612118B (zh) 用于引起针对hbv的免疫应答的病毒样粒子
JP2010516290A5 (https=)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
JP2015520188A5 (https=)
JP2015500827A5 (https=)
JPWO2019156137A5 (https=)
CN108883166A (zh) 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗
JP6757667B2 (ja) Cd28を介したシグナル伝達を阻害する短ペプチドによる炎症性疾病の症候の軽減
CN109153720B (zh) 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断
KR20140026372A (ko) 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
US12006343B2 (en) C4BP-based compounds for treating immunological diseases
JP2010535504A5 (https=)
CN102088992B (zh) 肽基二酰基甘油酯
CN108699548A (zh) 将生物包封于植物细胞中的治疗性蛋白质靶向递送至目标细胞类型以治疗疾病
JP2013545459A5 (https=)
EP3412288A1 (en) Vegf inhibitors for use for preventing and/or treating acne
RS56069B1 (sr) Faktor viii-izvedenih peptida za upotrebu u lečenju hemofilije a
JP2020536925A5 (https=)
CN115956078A (zh) Akt3调节剂及其使用方法
WO2023125600A1 (zh) 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品
JP7691414B2 (ja) メタロプロテアーゼadamts-7の免疫原性ペプチドセグメント、ならびに抗アテローム性動脈硬化症及び関連疾患におけるその使用
JP2014516407A5 (https=)
CN105120836A (zh) 具有胶原蛋白合成能力的新型的肽及其用途